Literature DB >> 35694693

Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.

Ashish Ranjan Dwivedi1, Vijay Kumar1, Vikash Prashar2, Akash Verma1, Naveen Kumar1, Jyoti Parkash2, Vinod Kumar1,3.   

Abstract

A series of morpholine substituted quinazoline derivatives have been synthesized and evaluated for cytotoxic potential against A549, MCF-7 and SHSY-5Y cancer cell lines. These compounds were found to be non-toxic against HEK293 cells at 25 μM and hence display anticancer potential. In these series compounds, AK-3 and AK-10 displayed significant cytotoxic activity against all the three cell lines. AK-3 displayed IC50 values of 10.38 ± 0.27 μM, 6.44 ± 0.29 μM and 9.54 ± 0.15 μM against A549, MCF-7 and SHSY-5Y cancer cell lines. Similarly, AK-10 showed IC50 values of 8.55 ± 0.67 μM, 3.15 ± 0.23 μM and 3.36 ± 0.29 μM against A549, MCF-7 and SHSY-5Y, respectively. In the mechanistic studies, it was found that AK-3 and AK-10 inhibit the cell proliferation in the G1 phase of the cell cycle and the primary cause of death of the cells was found to be through apoptosis. Thus, morpholine based quinazoline derivatives have the potential to be developed as potent anticancer drug molecules. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2022        PMID: 35694693      PMCID: PMC9132193          DOI: 10.1039/d2md00023g

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  33 in total

1.  The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells.

Authors:  S Jantová; S Letasiová; A Repický; R Ovádeková; B Lakatos
Journal:  Cell Biochem Funct       Date:  2006 Nov-Dec       Impact factor: 3.685

Review 2.  Progress in targeting the BCL-2 family of proteins.

Authors:  Thomas P Garner; Andrea Lopez; Denis E Reyna; Adam Z Spitz; Evripidis Gavathiotis
Journal:  Curr Opin Chem Biol       Date:  2017-08-17       Impact factor: 8.822

3.  Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Authors:  Sonali M Smith; Kerri Wachter; Howard A Burris; Richard L Schilsky; Daniel J George; Douglas E Peterson; Melissa L Johnson; Merry Jennifer Markham; Kathryn F Mileham; Muhammad S Beg; Johanna C Bendell; Robert Dreicer; Vicki L Keedy; Randall J Kimple; Miriam A Knoll; Noelle LoConte; Helen MacKay; Jane Lowe Meisel; Timothy J Moynihan; Daniel A Mulrooney; Therese Marie Mulvey; Olatoyosi Odenike; Nathan A Pennell; Katherine Reeder-Hayes; Cardinale Smith; Ryan J Sullivan; Robert Uzzo
Journal:  J Clin Oncol       Date:  2021-02-02       Impact factor: 44.544

4.  8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells.

Authors:  Yiwen Zhang; Zhimei Li; Qiuxia Min; Abulizi Palida; Yiyuan Zhang; Ruotian Tang; Lixia Chen; Hua Li
Journal:  Bioorg Chem       Date:  2018-02-02       Impact factor: 5.275

Review 5.  FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Weishi Yuan; Kun He; Patricia Keegan; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

6.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

7.  Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer.

Authors:  Ashish Ranjan Dwivedi; Amandeep Thakur; Vijay Kumar; Ira Skvortsova; Vinod Kumar
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

8.  FDA drug approval summary: erlotinib (Tarceva) tablets.

Authors:  Martin H Cohen; John R Johnson; Yeh-Fong Chen; Rajeshwari Sridhara; Richard Pazdur
Journal:  Oncologist       Date:  2005-08

Review 9.  Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.

Authors:  Kishor S Jain; Jitender B Bariwal; Muthu K Kathiravan; Manisha S Phoujdar; Rajkumari S Sahne; Bishram S Chauhan; Anamik K Shah; Mange Ram Yadav
Journal:  Bioorg Med Chem       Date:  2008-03-04       Impact factor: 3.641

Review 10.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.